Zynerba Press Releases

13 Jan 20 Zynerba Pharmaceuticals Announces Achievement of Enrollment Target in Phase 2 Trial of Zygel™ in Autism Spectrum Disorder

12 Nov 19 Zynerba Pharmaceuticals Receives New U.S. Patent for Treatment of Fragile X Syndrome with Transdermal Cannabidiol

5 Nov 19 Zynerba Pharmaceuticals Reports Third Quarter 2019 Financial Results and Operational Highlights

25 Oct 19 Zynerba Pharmaceuticals to Present at the Dawson James Securities 5th Annual Small Cap Growth Conference

26 Sep 19 Zynerba Pharmaceuticals to Present at the 2019 Cantor Global Healthcare Conference

18 Sep 19 Zynerba Pharmaceuticals Announces Positive Top Line Data from BELIEVE 1 Open Label Phase 2 Study of Zygel™ in Developmental and Epileptic Encephalopathies (DEE)

5 Sep 19 Autism Spectrum Disorder, Fragile X Syndrome, and 22q11.2 Deletion Syndrome Share a Constellation of Sociobehavioral Symptoms

5 Sep 19 New Caregiver-Reported Data Further Validate the Use of the Aberrant Behavior Checklist Community: FXS Specific (ABC-CFXS) Subscales to Assess Core Behavioral Symptoms of Fragile X Syndrome (FXS)

3 Sep 19 Zynerba Pharmaceuticals to Present at Two Upcoming Conferences

29 Aug 19 Zynerba Pharmaceuticals Announces Poster Presentations at the 22nd Society for the Study of Behavioural Phenotypes (SSBP) Symposium